Literature DB >> 30764648

Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Boadie W Dunlop1, Devon LoParo1, Becky Kinkead1, Tanja Mletzko-Crowe1, Steven P Cole1, Charles B Nemeroff1, Helen S Mayberg1, W Edward Craighead1.   

Abstract

OBJECTIVE: Adults with major depressive disorder frequently do not achieve remission with an initial treatment. Addition of psychotherapy for patients who do not achieve remission with antidepressant medication alone can target residual symptoms and protect against recurrence, but the utility of adding antidepressant medication after nonremission with cognitive-behavioral therapy (CBT) has received little study. The authors aimed to evaluate the acute and long-term outcomes resulting from both sequences of combination treatments.
METHODS: Previously untreated adults with major depression who were randomly assigned to receive escitalopram, duloxetine, or CBT monotherapy and completed 12 weeks of treatment without achieving remission entered an additional 12 weeks of combination treatment. For patients who did not achieve remission with CBT, escitalopram was added (CBT plus medication group) to their treatment, and for those who did not achieve remission with an antidepressant, CBT was added (medication plus CBT group) to their treatment. Patients who responded to the combination treatment entered an 18-month follow-up phase to assess risk of recurrence.
RESULTS: A total of 112 patients who did not achieve remission with a monotherapy entered combination treatment (41 who responded to monotherapy but did not achieve remission and 71 who did not respond to monotherapy). Overall, remission rates after subsequent combination therapy were significantly higher among patients who responded to monotherapy but did not achieve remission (61%) than among patients who did not respond to monotherapy (41%). Among patients who responded to monotherapy but did not achieve remission, the remission rate in the CBT plus medication group (89%) was higher than in the medication plus CBT group (53%). However, among patients whose depression did not respond to monotherapy, rates of response and remission were similar between the treatment arms. Higher levels of anxiety, both prior to monotherapy and prior to beginning combination treatment, predicted poorer outcomes for both treatment groups.
CONCLUSIONS: The order in which CBT and antidepressant medication were sequentially combined did not appear to affect outcomes. Addition of an antidepressant is an effective approach to treating residual symptoms for patients who do not achieve remission with CBT, as is adding CBT after antidepressant monotherapy. Patients who do not respond to one treatment modality warrant consideration for addition of the alternative modality.

Entities:  

Keywords:  Antidepressive Agent; Anxiety; Depression; Duloxetine; Escitalopram; Psychotherapy; Relapse

Mesh:

Substances:

Year:  2019        PMID: 30764648      PMCID: PMC6557125          DOI: 10.1176/appi.ajp.2018.18091075

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  54 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

2.  Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review.

Authors:  Giovanni A Fava; Alessia Gatti; Carlotta Belaise; Jenny Guidi; Emanuela Offidani
Journal:  Psychother Psychosom       Date:  2015-02-21       Impact factor: 17.659

3.  Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project.

Authors:  Katja Wiethoff; Michael Bauer; Thomas C Baghai; Hans-Jürgen Möller; Robert Fisher; Dorothea Hollinde; Julia Kiermeir; Iris Hauth; Gerd Laux; Joachim Cordes; Peter Brieger; Klaus-Thomas Kronmüller; Joachim Zeiler; Mazda Adli
Journal:  J Clin Psychiatry       Date:  2010-07-13       Impact factor: 4.384

Review 4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments.

Authors:  Sagar V Parikh; Lena C Quilty; Paula Ravitz; Michael Rosenbluth; Barbara Pavlova; Sophie Grigoriadis; Vytas Velyvis; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

5.  Clinical management--imipramine/placebo administration manual. NIMH Treatment of Depression Collaborative Research Program.

Authors:  J Fawcett; P Epstein; S J Fiester; I Elkin; J H Autry
Journal:  Psychopharmacol Bull       Date:  1987

6.  Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study.

Authors:  Boadie W Dunlop; Mary E Kelley; Vivianne Aponte-Rivera; Tanja Mletzko-Crowe; Becky Kinkead; James C Ritchie; Charles B Nemeroff; W Edward Craighead; Helen S Mayberg
Journal:  Am J Psychiatry       Date:  2017-03-24       Impact factor: 18.112

7.  Cognitive therapy vs medications in the treatment of moderate to severe depression.

Authors:  Robert J DeRubeis; Steven D Hollon; Jay D Amsterdam; Richard C Shelton; Paula R Young; Ronald M Salomon; John P O'Reardon; Margaret L Lovett; Madeline M Gladis; Laurel L Brown; Robert Gallop
Journal:  Arch Gen Psychiatry       Date:  2005-04

Review 8.  Antidepressant drug effects and depression severity: a patient-level meta-analysis.

Authors:  Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett
Journal:  JAMA       Date:  2010-01-06       Impact factor: 56.272

9.  Effectiveness of cognitive behavior therapy for diagnostically heterogeneous groups: a benchmarking study.

Authors:  Peter M McEvoy; Paula Nathan
Journal:  J Consult Clin Psychol       Date:  2007-04

10.  Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis.

Authors:  Pim Cuijpers; Marit Sijbrandij; Sander L Koole; Gerhard Andersson; Aartjan T Beekman; Charles F Reynolds
Journal:  World Psychiatry       Date:  2014-02       Impact factor: 49.548

View more
  8 in total

1.  Challenges of Mood Disorders Care.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

2.  Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms: A Randomized Clinical Trial.

Authors:  Zindel V Segal; Sona Dimidjian; Arne Beck; Jennifer M Boggs; Rachel Vanderkruik; Christina A Metcalf; Robert Gallop; Jennifer N Felder; Joseph Levy
Journal:  JAMA Psychiatry       Date:  2020-06-01       Impact factor: 21.596

3.  Do Cognitive Therapy Skills Neutralize Lifetime Stress to Improve Treatment Outcomes in Recurrent Depression?

Authors:  Jeffrey R Vittengl; Sonja Stutzman; Aparna Atluru; Robin B Jarrett
Journal:  Behav Ther       Date:  2019-11-27

4.  The D*Phase-study: study protocol for a pragmatic two-phased, randomised controlled (non-inferiority) trial that addresses treatment non-response and compares cognitive behavioural therapy and short-term psychodynamic supportive psychotherapy for major depression.

Authors:  M F Miggiels; P M Ten Klooster; S Bremer-Hoeve; J J M Dekker; M J H Huibers; E Reefhuis; H L Van; M K van Dijk
Journal:  BMC Psychiatry       Date:  2021-05-04       Impact factor: 3.630

5.  Evaluation of the Effect of Comprehensive Nursing in Psychotherapy of Patients with Depression.

Authors:  Jialing Liu; Zhiyuan Xun
Journal:  Comput Math Methods Med       Date:  2021-10-26       Impact factor: 2.238

6.  Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety-A Role for Bile Acids.

Authors:  Siamak MahmoudianDehkordi; Sudeepa Bhattacharyya; Christopher R Brydges; Wei Jia; Oliver Fiehn; A John Rush; Boadie W Dunlop; Rima Kaddurah-Daouk
Journal:  Front Neurosci       Date:  2022-07-20       Impact factor: 5.152

Review 7.  Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug?

Authors:  Guido K W Frank
Journal:  Expert Opin Pharmacother       Date:  2020-04-13       Impact factor: 3.889

8.  Smartphone Psychological Therapy During COVID-19: A Study on the Effectiveness of Five Popular Mental Health Apps for Anxiety and Depression.

Authors:  Jamie M Marshall; Debra A Dunstan; Warren Bartik
Journal:  Front Psychol       Date:  2021-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.